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Background: Nitric oxide can be measured at multiple flow rates to determine proximal (maximum airway nitric
oxide flux; JawNO) and distal inflammation (alveolar nitric oxide concentration; CANO). The main aim was to study the
association among symptoms, lung function, proximal (maximum airway nitric oxide flux) and distal (alveolar nitric
oxide concentration) airway inflammation in asthmatic children treated and not treated with inhaled glucocorticoids.
Methods: A cross-sectional study with prospective data collection was carried out in a consecutive sample of girls and
boys aged between 6 and 16 years with a medical diagnosis of asthma. Maximum airway nitric oxide flux and alveolar
nitric oxide concentration were calculated according to the two-compartment model. In asthmatic patients, the asthma
control questionnaire (CAN) was completed and forced spirometry was performed. In controls, differences between the
sexes in alveolar nitric oxide concentration and maximum airway nitric oxide flux and their correlation with height were
studied. The correlation among the fraction of exhaled NO at 50 ml/s (FENO50), CANO, JawNO, forced expiratory volume
in 1 second (FEV1) and the CAN questionnaire was measured and the degree of agreement regarding asthma control
assessment was studied using Cohen’s kappa.
Results: We studied 162 children; 49 healthy (group 1), 23 asthmatic participants without treatment (group 2) and
80 asthmatic patients treated with inhaled corticosteroids (group 3). CANO (ppb) was 2.2 (0.1-4.5), 3 (0.2-9.2) and 2.45
(0.1-24), respectively. JawNO (pl/s) was 516 (98.3-1470), 2356.67 (120–6110) and 1426 (156–11805), respectively. There
was a strong association (r = 0.97) between FENO50 and JawNO and the degree of agreement was very good in group 2
and was good in group 3. There was no agreement or only slight agreement between the measures used to monitor
asthma control (FEV1, CAN questionnaire, CANO and JawNO).
Conclusions: The results for CANO and JawNO in controls were similar to those found in other reports. There was no
agreement or only slight agreement among the three measure instruments analyzed to assess asthma control. In our
sample, no additional information was provided by CANO and JawNO.Background
Asthma is a chronic inflammatory disease characterised by
recurrent symptoms of cough, wheezing and/or respiratory
distress, associated with variable airway obstruction and
bronchial hyperresponsiveness [1].
The Global Initiative for Asthma (GINA) [2] indicates
that the severity of asthma should be determined on the
basis of the degree of control in the corresponding treat-* Correspondence: osardon@gmail.com
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unless otherwise stated.ment step, which is achieved by assessing the frequency
of symptoms, the need for rescue bronchodilators, and
pulmonary function [3]. To assess deterioration, question-
naires can be used that evaluate patients’ perceptions of
their disease control. The only questionnaire developed
and validated in the Spanish pediatric population is the
CAN questionnaire [4].
Our group recently studied the association among
symptoms, pulmonary function, and fraction of exhaled
nitric oxide (FENO) for the management of asthma in
children [5] and, like other authors [6], we found that
the association–despite being significant–was weak.
The growing interest in modelling exhaled nitric oxide
is understandable because only an extended NO analysisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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FENO is inherently non-specific regarding the origin of
NO in the lungs and the recommended exhalation flow
of 50 ml/s (FENO,50) identifies inflammatory activity
mainly in the proximal airway or bronchi but the distal
contributions are effectively ignored. However, applying
mathematical models, the NO signal con be partitioned
into proximal [maximum airway NO flux (J’awNO)] and
distal (CANO) airway which could indirectly reflect
inflammatory activity in more distal areas (alveolar-
capillary interface) [7]. There is a lack of standardization
in the technique to determine CANO and J’awNO. In this
study, the two-compartment model and Tsoukias and
George’s equation was applied [8], however, other, more
complex models have been developed [9-11]. Several
authors have reported an association between elevated
CANO values and poor asthma control [12,13], persistent
nocturnal symptoms, severe treatment-refractory asthma,
and the risk of exacerbations [14].
The main aim of the present study was to study the
association and correlation among symptoms, pulmonary
function, proximal [maximum airway NO flux (J’awNO)]
and distal (CANO) airway inflammation with a view to
aiding the management of asthma in daily clinical practice.
The second objective was to determine alveolar NO in a
healthy population.Methods
Design of the study
A cross-sectional study with prospective data collection
was carried out in a consecutive sample of girls and boys
aged between 6 and 16 years with a medical diagnosis
of asthma according to GINA 2012 criteria [2], recruited
in the outpatient clinic of the Pediatric Pneumology
Section of Donostia Hospital between January and
August 2012.Study population
Untreated asthmatic patients and asthmatic patients
receiving inhaled glucocorticoid therapy as part of their
standard care were included. Patients were excluded if
they had asthma exacerbations or acute respiratory
infection at the consultation. A control group was consecu-
tively recruited during the same time period consisting
of healthy girls and boys aged between 6 and 16 years.
In this group, care was taken to ensure the absence of
asthma, allergic rhinitis, food allergy or atopic dermatitis
in the clinical history and on physical examination.
Primary exclusion criteria consisted of patients not meet-
ing the inclusion criteria, those with associated diseases,
those who were incapable of collaborating and/or children,
parents and/or guardians who refused to participate.Definitions
Asthma severity and control were classified according to
the GINA 2012 criteria [2]. Among the asthmatic group,
allergic rhinitis was considered to be present when there
were signs and symptoms compatible with this diagnosis,
a positive result to one or more aeroallergens in serum-
specific IgE testing (class III or higher) and/or a positive
skin prick test; food allergy when there were signs and
symptoms compatible with specific IgE in blood (class
III or higher), and atopic dermatitis when there were
compatible signs and symptoms [2,3].
Methodology
In both groups, CANO and J’awNO were determined
through the multiple exhalation flow technique at 50,
100 and 200 ml/s. Measurements were made by on-line
recording and the stationary chemiluminescence analyzer,
Eco Medics CLD 88 SP®, was used with DENOX 88 adap-
tive flow control. Flow and volume were calibrated daily
and NO gas was also calibrated monthly.
All children were instructed to exhale, starting from the
level of maximum inspiration, at 3 constant expiratory
flow rates (50, 100 and 200 ml/s). The manoeuver was
performed in triplicate, with calculation of the mean
value of the three measurements obtained for each flow
rate. First, determinations were performed at a flow rate of
50 ml/s, followed by 100 ml/s and finally at 200 ml/s. All
measurements were made in accordance with the recom-
mendations of the European Respiratory Society (ERS) and
the American Thoracic Society (ATS), published in 2005
[15]. The coefficient of variability among the three deter-
minations had to be within 10%. After NO determinations
had been obtained at different flow rates, CANO and
J’awNO were calculated by applying the two-compartment
model and Tsoukias and George’s equation [8].
In all asthmatic patients, after NO determination, forced
spirometry was performed (MasterLab. Version 5.3. Viasis®,
Wuerzburg, Germany) according to ATS/ERS recommen-
dations [16]. The equations proposed by Zapletal were used
to calculate the percentage of normality [17,18].
A medical history and physical examination were also
performed and the asthma control questionnaire (CAN)
[4] was completed by the parents (children younger than
9 years) or by the children and adolescents (older than
9 years). The CAN questionnaire consists of nine questions
that explore various aspects of asthma control in the previ-
ous 4 weeks. Responses are coded numerically and a total
score is calculated, ranging from 0 (better control) to 36
(worse control). The questionnaires were delivered and col-
lected before the clinical evaluation and lung function tests.
Statistical analysis
The quantitative variables analysed were age (years), weight
(kg), height (cm), NO determination (ppb) at 3 expiratory
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and J’awNO (pl/s). In the asthmatic group, the following
variables were also gathered: CAN questionnaire score
(points), forced expiratory volume in 1 second (FEV1 as a
percentage of the predicted value), forced vital capacity
(FVC as a percentage of the predicted value), the FEV1/
FVC ratio (as a percentage of the predicted value) and
forced expiratory flow between 25% and 75% of FVC
(FEF25–75 as a percentage of the predicted value).
The qualitative variables studied were sex and personal
atopy (atopic dermatitis, allergic rhinitis, food allergy
and aeroallergen sensitization). In asthmatic participants,
asthma severity was also analysed, as well as inhaled cor-
ticosteroid therapy and the degree of control.
Spearman’s rho was used to analyse the association
between CANO and J’awNO with FENO.50,100,200, FEV1 and
the CAN questionnaire. Given that personal atopy and
current treatment with inhaled glucocorticoids can act as
confounding factors in the FENO,50, CANO and J’awNO
values obtained, the statistical analysis was adjusted by
these variables using multiple lineal regression.
Cohen’s kappa coefficient was used to assess the degree
of agreement, with categorization of the variables accord-
ing to normal values, between CANO, J’awNO, FEV1,
FENO,50, and the CAN questionnaire.
In line with prior publications, the cutoff point for
normal values was defined as ≤ 25 ppb for FENO,50
[19,20], ≥80% for the relative value of FEV1 (% pre-
dicted) [1,2] and a score of less than 8 points for the
CAN questionnaire [4]. For CANO and J’awNO, the cut-
off for normal values was established on the basis of the
upper limit of the control group (<4.5 ppb for CANO
and <1470 pl/s for J’awNO).
In the control group, the Mann–Whitney test was
used to study differences in CANO and J’awNO by sex
and Spearman’s rho was used to study the association
between height and CANO and between height and
J’awNO.
Chi-square test was used for qualitative variables (sex),
Student’s t-test and ANOVA were used for quantitative
variables which followed normal distribution (age, weight,
and height) and Kruskal Wallis and Mann–Whitney U
test were used for quantitative variables which did not
follow normal distribution (FENO,50 J’awNO CANO).
Sample size
The sample size was estimated based on the correl-
ation coefficients expected according to published data
[12-14,21]. An alpha level of 5% was established for all tests
and the SYSTAT 9.0™ was used for the statistical analysis.
Ethics
This study was approved by the Ethics and Research
Committee at the Donostia University Hospital. Informedconsent was obtained from all participants. The parents’
and/or guardians’ permission, as well as that of the par-
ticipating child, if required by current legislation, was
obtained for data exploitation.
Results
Characteristics of the study population
The cohort consisted of 162 participants. In 158 (97.5%),
all determinations were successfully completed, distrib-
uted in group 1 (healthy controls, n = 49 [32.2%]), group 2
(untreated asthmatic patients, n = 23 [15.1%]) and group 3
(asthmatic patients receiving inhaled glucocorticoid ther-
apy, n = 80 [52.5%]).
Four participants (2.4%) were excluded due to poor
technique and a further 6 participants (100% asthmatic)
were excluded because the NO determination did not
follow the linear model (negative CANO values). Age,
weight, FENO,50 and spirometry were analysed in these
individuals and no significant differences were found
compared with included participants. The characteristics
of the study population are shown in Table 1.
No significant differences were found in age, weight,
height or sex among the 3 study groups. In addition, no
differences were found in gender and height between
asthma (group 2 y 3) and control group (group 1) (p = 0.21
and p = 0.15 respectively). Moreover, there were no signifi-
cant differences in gender and height between untreated
asthmatic patients (group 2) and asthmatic patients receiv-
ing inhaled glucocorticoid therapy (group 3) (p = 0.31 and
p = 0.19 respectively).
In the control group, no significant differences were
found in CANO or J’awNO by sex.
Similarly, no statistically significant associations were
found between height and J’awNO (r = 0.15, p > 0.05) or
between height and CANO (r = 0.22, p > 0.05).
Asthmatic patients
In general, asthmatic participants had mild asthma
that was well controlled [median CAN questionnaire
score: 5 (0–29)] and normal baseline spirometry (mean
FEV1 = 99.7%; mean FEV1/FVC = 85%). Asthmatic partici-
pants receiving no treatment of any type (group 2) had
higher CANO, J’awNO and FENO,50 values than asthmatic
participants receiving inhaled glucocorticoid therapy
(group 3): CANO (median and range) 3 ppb (0.2-9.2),
J’awNO 2356.67 pl/s (120–6110) and FENO,50 48.3 ppb
(7.4-122) versus CANO 2.4 ppb (0.1-24), J’awNO 1426 pl/s
(156–11805) and FENO,50 32 ppb (3.5-234). This difference
was statistically significant for J’awNO (p = 0.001) and
FENO,50 (p = 0.002) (Table 1).
Asthmatic participants with poor or partial asthma
control [2] (n = 25; 24.2%) had higher CANO, J’awNO and
FENO,50 values than asthmatic participants with good
control [2] (n = 78; 75.7%): CANO (median and range)
Table 1 Characteristics of the study population Group 1 (healthy controls), group 2 (untreated asthmatic patients) and
group 3 (asthmatic patients receiving inhaled glucocorticoid therapy)
Group 1 (N = 49) Group 2 (N = 23) Group 3 (N = 80) p
Age (years) (mean ± SD) 10.1 ± 1.9 9.3 ± 2.06 10.7 ± 2.85 NS
Sex F/M 28/21 10/13 29/51 NS
Weight (kg) (mean ± SD) 38 ± 13.9 36 ± 10.3 42.1 ± 15.2 NS
Height (cm) (mean ± SD) 139.4 ± 13.2 137.7 ± 11.5 144.84 ± 16.2 NS
Atopic dermatitis N (%) 0 8 (34.7) 30 (37.5)
Allergic rhinitis N (%) 0 19 (82.6) 70 (87.5)
Food allergy N (%) 0 0 12 (15)
Mild asthma N (%) 0 19 (82.6) 57 (71.2)
Moderate asthma N (%) 0 4 (17.4) 23 (28.7) NS
Degree of control N (%)
- Good 0 15 (65.2) 63 (78.7) NS
- Partial 0 6 (26) 11 (13.7)
- Poor 0 2 (8.7) 6 (7.5)
ICS dose (fluticasone mcg) (mean ± SD) 0 0 135.45 (35.2)
CAN (median and range) 0 5 (0–29) 5 (0–27) NS
FEV1 (mean ± SD) 0 98.17 (15.07) 99.65 (10.59) NS
FENO,50 (ppb) (median and range) 11.5 (1.6-27.3) 48.3 (7.4-122) 32 (3.5-234) p = 0.002 (2 vs 3) p < 0.001 (1 vs 2 and 3)
J’awNO (pl/s) (median and range) 516 (98.3-1470) 2356.7 (120–6110) 1426 (156–11805) p = 0.001 (2 vs 3) p < 0.001 (1 vs 2 and 3)
CANO (ppb) (median and range) 2.2 (0.1-4.5) 3.0 (0.2-9.2) 2.4 (0.1-24) NS ( 2 vs 3) P = 0.022 (1 vs 2 and 3)
F: female; M: male; SD: standard deviation; J’awNO: maximum airway NO flux; CANO: alveolar nitric oxide concentration; FENO,50: fraction of exhaled nitric oxide at a
flow rate of 50 ml/s; CAN: asthma control questionnaire; FEV1: forced expiratory volume in 1 second; ppb: parts per billion; pl/s: picolitre/second; NS: no significant
differences (p > 0,05); vs: versus.
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FENO,50 51.9 ppb (8.6-209) versus CANO 2.3 ppb (0.1-24),
J’awNO 1445 pl/s (120–11805) and FENO,50 32.5 ppb
(3.5-234). This difference was not statistically signifi-
cant (p = 0.4) for CANO, but was statistically significant
for J’awNO (p = 0.01) and FENO,50 (p = 0.006) (Figure 1).
No significant differences (p > 0.05) were found for any
of the spirometric variables between the group of patients
with good asthma control and the group with poor or
partial asthma control.Differences between asthmatic patients and healthy
participants
FENO,50 was significantly higher in the asthmatic groups
(groups 2 and 3) than in the group of healthy participants
(group 1): median and range; 35.4 ppb (3.5-234) versus
11.5 ppb (1.6-27.3) (p < 0.001). J’awNO was also higher in
the asthmatic group than in the control group; 1703 pl/s
(120–11805) versus 516 pl/s (98.33-1470) (p < 0.001).
Similarly, CANO was higher in the asthmatic group
than in the control group: 2.7 ppb (0.1-24) versus
2.2 ppb (0.1-4.5) (p = 0.022) (Table 1). We did also a
separate analysis between group 1 (healthy participants)
and group 2 (untreated asthmatic patients) and nosignificant differences were found among the results
obtained.Association and degree of agreement among FENO,50,
CAN, FEV1, CANO and J’awNO
A close and significant association was found between
J’awNO and FENO,50 (r = 0.97; p < 0.05). No association
(CANO and J’awNO), or only a weak association, was
found between J’awNO and CAN scores, J’awNO and FEV1,
CANO and FEV1, CANO and CAN scores and between
FEV1 and CAN scores. On categorizing the variables
(FENO,50, CAN questionnaire, FEV1, CANO and J’awNO)
according to normal values, there was an optimal degree
of agreement between FENO,50 and J’awNO, in the 2 groups
of asthmatic patients. This agreement was almost perfect
for group 2 (KC = 0.89) and was substantial (KC = 0.71)
for group 3. No agreement, or only slight agreement to
establish the degree of asthma control was found between
J’awNO and CAN scores (KC = 0.34), J’awNO and FEV1
(KC = 0.123), CANO and FEV1 (KC = 0.104), CANO and
CAN scores (KC = 0.03), CANO and J’awNO (KC = 0.074)
and between FEV1 and CAN scores (KC = 0.12).
The statistical analysis was adjusted by current treat-
ment with inhaled glucocorticoids using multiple lineal
a) CANO (ppb)
Good control Poor control
b) J´awNO (pl/s)
Good control Poor control 
Figure 1 CANO and J’awNO in asthmatic patients with good
asthma control versus those with poor or partial control.
a). CANO (ppb), Good control Poor control. b). J’awNO (pl/s), Good
control Poor control. CANO: alveolar nitric oxide concentration; ppb:
parts per billion; J’awNO: maximum airway NO flux; pl/s: picolitres/
second; NS: non significant.
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the results obtained.
Discussion
Several guidelines and international consensus documents
for the management of asthma recommend evaluation
of clinical symptoms and lung function to establish the
degree of asthma control [1,2], without including assess-
ment of markers of inflammation such as NO, although
these documents suggest the possibility of performing
further studies to evaluate whether monitoring of suchmarkers could improve asthma management in clinical
practice [22]. In addition, several studies have shown that
distinguishing between NO from the proximal airway
(FENO,50 and J’awNO) and/or that from the distal airway
(CANO,) could be useful as a surrogate marker of airway
inflammation in the assessment of asthmatic patients,
although the role of this compartmentalization remains
to be determined in clinical practice and there is, as
yet, no standardised technique for the determination of
these parameters [12,23].
In this context, the main objective of this study was to
examine the association and degree of agreement among
symptoms, lung function (FEV1), proximal (J’awNO) and
distal (CANO) airway inflammation and asthma manage-
ment in a cohort of asthmatic children and teenagers. In
our sample, no additional information was provided to
assess asthma control by CANO and J’awNO.
Like other reports [3,21,24], in our cohort of asthmatic
patients (generally with mild and/or moderate asthma
and mostly well controlled), there was no significant
association between NO from the proximal (J’awNO) and
distal (CANO) (r = −0.001) airway, indicating that these
two determinations provide independent information.
However, J’awNO and FENO,50 were strongly associated
and showed optimal agreement, indicating that a flow
rate of 50 ml/s is sufficient for NO determination in the
proximal airway. J’awNO seems to provide no additional
information and consequently, FENO,50 could be sufficient
to characterize inflammation in the proximal airway
[24]. Proximal inflammation (FENO,50 and J’awNO) has
not consistently been associated with the degree of
asthma control or with the risk of exacerbations in
pediatric patients [25,26]. A possible explanation for
these findings is the presence of confounding factors
such as inhaled glucocorticoid therapy or atopy, which
influence NO from the proximal airway. In our sample,
asthmatic patients who were treated with inhaled glu-
cocorticoids as part of their standard care received low
or mild doses between 100 and 200 mcg per day. The
statistical analysis was adjusted by current treatment
with inhaled glucocorticoids using multiple lineal regres-
sion and no significant differences were found among the
results obtained.
In agreement with the findings of other authors [12,27],
in our cohort, we found no association (CANO and
J’awNO) or significant but weak association between
J’awNO and CAN scores, J’awNO and FEV1, CANO and
FEV1, CANO and CAN scores and between FEV1 and CAN
scores probably because the measurement instruments
used quantify distinct variables that influence asthma
differently and at distinct times. However, other authors
[12,13,21] have found differences between asthmatic
patients with elevated CANO and a poor score on the
Asthma Control Test (ACT) questionnaire and elevated
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in differences in the populations selected for study. Our
cohort of asthmatic (treated and untreated) patients
was, in general, a group with mild, well-controlled asthma
[median CAN questionnaire score: 5 (0–29)] and normal
baseline spirometry (mean FEV1 = 99.7%; mean FEV1/
FVC= 85%). They were included consecutively without
taking into account the severity of the disease. The inclu-
sion of a population with more severe asthma could
possibly have modified our results although we can not
be sure. Moreover, the inclusion of more untreated
asthmatic patients could also varied our results. However,
no significant difference were found in age, sex, height,
weight, lung function, symptoms, severity and control of
asthma between treated and untreated children.
In this sense, some authors [27,28] did not found associ-
ation between FENO,50, CANO, the level of asthma control
and severity of the disease in stable and unobstructed
asthmatic children and adults. Other authors, found
abnormal FENO,50 but normal CANO during asthma
exacerbations. Finally, Mahut et al. [29] concluded
that the usefulness of alveolar nitric oxide in asthma
remain to be established.
Given that some authors have shown significant differ-
ences in CANO determinations according to the method
used, the second objective of the study was to obtain
alveolar NO values (CANO) in our healthy population
with the method described previously [8]. The exclusion
criteria in this group were strict, leading to a small sam-
ple (n = 49) due to the obvious limitations in this group.
In our sample, values of CANO (median 2.2 ppb; range
0.1-4.5) and J’awNO (median 516 pl/s; range 98.33-1470
pl/s) were similar to those described by other authors
[12,21,24,30]. In contrast, Mahut et al. [7] found higher
CANO values (mean 4.2 ± 2 ppb) and lower J’awNO values
(mean 320 ± 130 pl/s). These differences could be explained
by the different populations studied and/or by differences
in the methodology used [31].
Unlike previous studies [24,30], in our cohort of healthy
children there were no differences in CANO or J’awNO in
relation to height or weight.
Our results show that the two-compartmental model
of NO exchange cannot be applied in approximately 6%
of asthmatic patients, which, according to the literature,
could be explained by differences in ventilation and
inflammatory patterns in some of these patients [32].
Our percentage is somewhat lower than that reported
by other authors [12,21].
One of the main limitations of this study is the lack of
standardization in the technique to determine CANO
and J’awNO. Although it is true that two-compartment
models [8] provide additional information on the degree
of alveolar (distal airway) and/or bronchial (proximal
airway) participation in inflammation, the simplificationleads to some limitations, such as the demonstrated axial
diffusion of NO and the geometry of the airways them-
selves, since it has been shown that there is some exchange
between the two compartments and that a proportion of
CANO may correspond to NO produced in the bronchial
compartment which, through retrograde axial diffusion,
reaches the alveoli.
Other, more complex models have been developed
[9,10], as well as a model of exhalation at multiple flows
that incorporates the retrograde axial diffusion model
and is adapted to the trumpet shape of the airway tree
[11]. Importantly, approximation of CANO and J’awNO
could be influenced by the range of flows selected [8].
The inclusion of flows that are too low could overesti-
mate CANO and underestimate J’awNO and could also be
uncomfortable for pediatric patients [24]. Moreover, flow
rates of around 200 ml/s is not always sufficient to
achieve a stable plateau in NO concentration curve. For
all these reasons, we chose to use expiratory flow rates
of between 50 and 200 ml/s.
Another limitation of this study is its cross-sectional
design, since we analysed a disease that varies over time by
determining pulmonary function and NO concentration at
a specific moment. Serial determinations could offer a more
faithful profile of inflammation and disease control in indi-
vidual patients according to their baseline values and those
during exacerbations.Conclusions
In summary, normal values of both CANO and J’awNO
obtained in this study were similar to those of other
published series. There was no agreement or only slight
agreement between the measures used to monitor asthma
control: FEV1, the CAN questionnaire, CANO and J’awNO.
This weak agreement was probably found because these
measures quantify variables that influence asthma in a
different way and at distinct moments. This is a cross-
sectional study and the status of the disease that varies
over time was analyzed in a particular moment. Therefore,
in that moment, the variables analyzed in each patient
may not be concordant. Although they are complemen-
tary, none of them can be exchanged for another in the
management of the disease in clinical practice. In our
sample, no additional information was provided to assess
asthma control by CANO and J’awNO.
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